Evaluation of Imaging in Advanced Lung Cancer
Test-retest Evaluation of [18F]F-AraG PET
Recruiting
Phase 2
Interventional Study
Non-small Cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 10 (estimated)
- Sponsor
- CellSight Technologies, Inc. · Industry
Who this trial is looking for
This trial is looking for patients with advanced lung cancer who are candidates for immunotherapy. Participants will have two imaging scans within a week to help understand how the imaging works over time.
Are You a Good Fit for This Trial?
You may be able to join if
- I am over 18 years old.
- I have been diagnosed with non-small cell lung cancer.
- I can receive immunotherapy for my condition.
- I have measurable disease.
- I have an ECOG performance status of 0, 1, or 2.
You may not be able to join if
- I have serious health problems that could interfere with this trial.
- I am pregnant or breastfeeding.
- I have severe claustrophobia.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore thes…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients (\>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease.
2. Measurable disease.
3. ECOG performance status of 0, 1 or 2.
Exclusion Criteria:
1. Serious …
Contacts